Welcome to our dedicated page for Research Solutions SEC filings (Ticker: RSSS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Research Solutions, Inc. (NASDAQ: RSSS) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into how Research Solutions reports its financial results, describes its vertical SaaS and AI business, and addresses governance and shareholder matters.
Research Solutions uses current reports on Form 8-K to announce events such as quarterly and annual financial results, preliminary earnings updates, and certain management or governance changes. For example, the company has filed 8-Ks to furnish press releases describing platform and transaction revenue, annual recurring revenue (ARR), gross margin trends, net income, and Adjusted EBITDA, as well as to disclose changes in executive roles.
The company’s proxy statement on Form DEF 14A outlines topics such as director elections, ratification of the independent registered public accounting firm, and advisory votes on executive compensation and the frequency of such votes. It also provides information about the virtual format of the annual meeting, voting procedures, and certain aspects of corporate governance and executive pay.
On this page, users can review Research Solutions’ 10-K and 10-Q filings (when available), which contain more extensive discussions of its vertical SaaS and AI model, revenue sources from platform subscriptions and transactions, risk factors, and segment information. Investors can also examine Form 4 insider transaction reports and other ownership-related filings to understand how officers, directors, and significant shareholders transact in RSSS stock.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, helping readers navigate lengthy documents such as annual reports or complex 8-K disclosures. Real-time updates from EDGAR ensure that new Research Solutions filings appear promptly, while AI explanations can assist users in interpreting financial metrics, non-GAAP measures like Adjusted EBITDA, and governance-related proposals.
Research Solutions, Inc. reported a return to profitability for the quarter ended December 31, 2025. Total revenue was $11.8 million, down slightly from $11.9 million a year earlier, as growth in software subscriptions offset weaker transactional sales.
Platforms revenue grew to $5.2 million, up 13.6%, while Transactions revenue declined 10.2% to $6.6 million. Gross profit increased to $6.2 million, expanding gross margin to 52.4% from 48.9%, helped by lower content costs.
Operating income rose sharply to $0.7 million from $0.1 million, with lower general and administrative and stock-based compensation expenses. Net income was $0.5 million, or $0.02 per diluted share, compared with a loss of $2.0 million, largely reflecting a much smaller non-cash loss on the Scite earnout revaluation.
For the six months, revenue was $24.1 million, up 0.6%, with Platforms up 15.8% and Transactions down 8.4%. Net income reached $1.3 million versus a $1.3 million loss. The company generated $2.5 million of operating cash flow and ended the period with $12.3 million in cash and no borrowings on its $0.5 million credit line.
Research Solutions, Inc. reported a profitable fiscal second quarter 2026, reversing a prior-year loss. Net income was $547,000, or $0.02 per diluted share, compared with a net loss of $2.0 million a year earlier. Adjusted EBITDA rose to $1.3 million, up 35.6%.
Total revenue was $11.8 million, down 1.0%, as strong growth in higher-margin Platform subscriptions offset weaker Transaction revenue. Platform revenue grew 13.6% to $5.2 million, and total annual recurring revenue reached $21.8 million, up 13.9% year-over-year. Gross margin expanded to 52.4%, while operating expenses declined 5.1%, supporting improved profitability and cash generation.
A director of Research Solutions, Inc. reported receiving an option to purchase 50,000 shares of the company’s common stock. The stock option was granted on 11/12/2025 with an exercise price of $3.07 per share and an expiration date of 11/11/2035. The option was reported as directly owned and carried a price of $0 at grant, indicating it was an award rather than a market purchase.
According to the vesting terms, one-third of the options vest on November 12, 2026, and one-twelfth of the options vest on the last day of each quarter beginning December 31, 2026 until fully vested. This creates a multi‑year vesting schedule that ties the director’s potential ownership to ongoing service and future company performance.
Research Solutions, Inc. reported that one of its directors exercised stock options to acquire 75,000 shares of common stock on 11/12/2025 at an exercise price of $0.7 per share. Following this transaction, the director directly beneficially owns 484,608 shares of the company’s common stock.
On the same date, the director was granted a new option to purchase 50,000 shares of common stock at an exercise price of $3.07 per share, expiring on 11/11/2035. According to the vesting schedule, one third of these options vest on November 12, 2026 and one twelfth vest on the last day of each quarter beginning December 31, 2026 until fully vested, while the previously held option for 75,000 shares at $0.7 was fully exercised and now shows 0 remaining.
Research Solutions, Inc. (RSSS) director Form 4 reports an option exercise and share acquisition. On 11/17/2025, the reporting director exercised an option to purchase 150,000 shares of common stock at an exercise price of $0.70 per share, coded as transaction type "M" (option exercise). After this transaction, the director beneficially owned 318,500 shares of common stock directly and 75,000 shares indirectly through an IRA. A corresponding entry in the derivative table shows the option to purchase 150,000 shares at $0.70, originally exercisable on 12/04/2015 and expiring on 12/03/2025, with zero derivative securities remaining following this exercise.
Research Solutions, Inc. (RSSS) reported that one of its directors received an option grant for 60,000 shares of common stock on 11/12/2025 at an exercise price of $3.07 per share. These stock options expire on 11/11/2035, giving the holder a long window to buy shares at that price if they choose.
The options vest over time. One-third of the grant vests on 11/12/2026, and the remaining two-thirds vest in equal installments on the last day of each quarter beginning 12/31/2026 until fully vested. Following this transaction, the reporting person directly holds 60,000 derivative securities (stock options) tied to Research Solutions common stock.
Research Solutions, Inc. (RSSS) reported a new equity award to one of its directors on a Form 4. On November 12, 2025, the director was granted an option to purchase 50,000 shares of common stock at an exercise price of $3.07 per share, expiring on November 11, 2035. The option was acquired as a direct holding with no cash price for the derivative itself. The vesting schedule provides that one-third of the options vest on November 12, 2026, and one-twelfth vest on the last day of each quarter beginning December 31, 2026 until fully vested.
Research Solutions, Inc. (RSSS) reported that one of its directors received an option grant to purchase 50,000 shares of common stock on 11/12/2025. The stock options have an exercise price of $3.07 per share and expire on 11/11/2035. According to the vesting schedule, one-third of the options vest on November 12, 2026, with the remaining options vesting in equal quarterly installments on the last day of each quarter beginning December 31, 2026 until fully vested. The options are held as direct ownership by the reporting person.
Research Solutions, Inc. reported a stronger quarter for the period ended September 30, 2025. Revenue rose to $12,312,185 (up 2.2%), driven by Platforms revenue of $5,120,840 (up 18.3%), while Transactions declined to $7,191,345 (down 6.8%). Gross margin improved to 50.6% from 47.9%, lifting income from operations to $961,671 (up 48.7%).
Net income increased to $749,387 from $669,004, with basic and diluted EPS at $0.02. Operating cash flow was $1,107,119. Cash and equivalents were $11,955,763, and deferred revenue was $9,982,074, reflecting advance-billed SaaS subscriptions.
The company continued settling the Scite acquisition earnout: a first payment in August 2025 included $1,304,909 cash and 264,924 shares; a second installment on November 3, 2025 included $1.2M cash and 222,072 shares. The contingent earnout liability measured at fair value (Level 3) was $12,332,983 at quarter end. A $500,000 revolving credit line remained undrawn. Shares outstanding were 32,866,068 as of November 7, 2025.
Research Solutions, Inc. filed a current report to share that it has announced financial results for its first quarter of fiscal year 2026, covering the quarter ended September 30, 2025. The company furnished, rather than filed, a press release as an exhibit, meaning the detailed results are provided for information but are not incorporated into other filings unless specifically referenced.
The press release, titled “Research Solutions Reports First Quarter Fiscal Year 2026 Results,” is attached as Exhibit 99.1, with an additional exhibit covering the electronic cover page data. The filing was signed by the company’s Chief Financial Officer, William Nurthen.